

## Regulatory Story

[Go to market news section](#)



|                 |                               |
|-----------------|-------------------------------|
| <b>Company</b>  | <a href="#">CustomVis plc</a> |
| <b>TIDM</b>     | CUS                           |
| <b>Headline</b> | AGM Statement                 |
| <b>Released</b> | 10:00 11-Feb-2010             |
| <b>Number</b>   | 9890G10                       |

RNS Number : 9890G

CustomVis plc

11 February 2010

11 February 2010

**CustomVis plc**  
("CustomVis" or "the Company")

### AGM Statement

At the Annual General Meeting of CustomVis to be held at 10.00 a.m. this morning, Simon Carroll, Chairman of the Company, will make the following statement:

"The Group has made a positive start to 2010, with a further contract for a laser into South America, which is quickly becoming one of our strongest territories. We continue our endeavours in other countries, where advanced negotiations are underway with a number of surgeons, some of which we expect to conclude in the coming weeks.

We are very pleased to report that our market opportunities have expanded with the regulatory approval to perform our PresBvis™ treatment for presbyopia, the condition that leads to the need for reading glasses. Indeed, our CEO, Paul van Saarloos, has recently become one of the first patients to undergo corrective surgery for presbyopia, using our newly pioneered PresBvis™ technique. We can report that his vision has been fully restored in the treated eye and he no longer needs glasses for reading, something he has done for the past 3 years. A key benefit from the ability to perform the PresBvis™ treatment is that surgeons have another reason to acquire the Pulzar Z1 laser as it provides them with another substantial market to address.

The directors expect the rest of the year to be an exciting one for the Group as we continue to make advances in our laser technology. We are also now seeing our first revenues from PresBvis™ and later in the calendar year, we expect to make the first sales for RetinaVis™, our new portable digital ophthalmoscope which photographs the retina of the eye. Negotiations with distributors for large volumes are currently underway.

Our key sales focus in 2010 will be on the mature European market, following the recent appointment of our European sales representative. This market promises to deliver higher margins to the Group and, the current series of clinical trials which are underway at Moorfields Hospital should hopefully provide the evidence we need to set ourselves favourably against the strongest of our competitors. The Moorfields trial is aiming to treat more difficult cases of irregular shaped eyes that traditionally have very few or no other options for treatment. Therefore, it is likely that the trial will take some time to complete and it is unlikely the full results will be available until later this calendar year.

CustomVis plans to announce its interim results in late March, when we will update shareholders more thoroughly with our various developments."

-ends-

**For further information, please contact:**

**CustomVis plc**

Simon Carroll, Chairman

+61 419 304 906

Paul van Saarloos, CEO

+61 410 497 456

**Merchant John East Securities Limited**

David Worlidge / Simon Clements

020 7628 2200

**Leander PR**

Christian Taylor-Wilkinson

07795 168 157

This information is provided by RNS  
The company news service from the London Stock Exchange

END

AGMBCGDDDSBBGGG

CLOSE

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. [Terms and conditions](#), including restrictions on use and distribution apply.

©2009 London Stock Exchange plc. All rights reserved

Regulatory